Abstract
Objectives Our objectives in this study were to determine the inhibitory effects of abatacept on joint damage and its clinical efficacy and safety in patients with rheumatoid arthritis (RA). Methods Fifty Japanese patients with RA were treated with abatacept for 24 weeks in routine clinical practice. Results At week 24, 20 % of patients achieved clinical remission [Simplified Disease Activity Index (SDAI) ≤3.3], whereas 50 % were in remission or had a low disease activity. Structural remission [progression of modified total Sharp score (ΔmTSS) ≤0.5] was achieved in 76 % of patients. The ΔmTSS decreased significantly from 7.1 ± 7.3 at baseline to 1.8 ± 5.7 at week 24. C-reactive protein (CRP) was the only independent prognostic factor for joint damage progression at week 24, whereas SDAI and matrix metalloproteinase-3 levels were not. A very high proportion of patients with CRP levels <1.5 mg/dl (88 %) achieved structural remission. In terms of safety, the retention rate for all patients was favorable (80 %), and stomatitis was the only adverse event observed. No patient withdrew from the study because of infections. Conclusions Abatacept has favorable clinical and structural effects, inhibits radiographic progression, and has a good safety profile in routine clinical practice.
| Original language | English |
|---|---|
| Pages (from-to) | 42-51 |
| Number of pages | 10 |
| Journal | Modern Rheumatology |
| Volume | 24 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - 2014 |
| Externally published | Yes |
Fingerprint
Keywords
- Abatacept
- Japanese patients
- Modified total Sharp score
- Radiographic outcome
- Rheumatoid arthritis
ASJC Scopus subject areas
- Rheumatology
Cite this
Abatacept inhibits radiographic progression in patients with rheumatoid arthritis : A retrospective analysis of 6 months of abatacept treatment in routine clinical practice. The ALTAIR study. / Kubo, Satoshi; Saito, Kazuyoshi; Hirata, Shintaro; Fukuyo, Shunsuke; Yamaoka, Kunihiro; Sawamukai, Norifumi; Nawata, Masao; Iwata, Shigeru; Mizuno, Yasushi; Tanaka, Yoshiya.
In: Modern Rheumatology, Vol. 24, No. 1, 2014, p. 42-51.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Abatacept inhibits radiographic progression in patients with rheumatoid arthritis
T2 - A retrospective analysis of 6 months of abatacept treatment in routine clinical practice. The ALTAIR study
AU - Kubo, Satoshi
AU - Saito, Kazuyoshi
AU - Hirata, Shintaro
AU - Fukuyo, Shunsuke
AU - Yamaoka, Kunihiro
AU - Sawamukai, Norifumi
AU - Nawata, Masao
AU - Iwata, Shigeru
AU - Mizuno, Yasushi
AU - Tanaka, Yoshiya
PY - 2014
Y1 - 2014
N2 - Objectives Our objectives in this study were to determine the inhibitory effects of abatacept on joint damage and its clinical efficacy and safety in patients with rheumatoid arthritis (RA). Methods Fifty Japanese patients with RA were treated with abatacept for 24 weeks in routine clinical practice. Results At week 24, 20 % of patients achieved clinical remission [Simplified Disease Activity Index (SDAI) ≤3.3], whereas 50 % were in remission or had a low disease activity. Structural remission [progression of modified total Sharp score (ΔmTSS) ≤0.5] was achieved in 76 % of patients. The ΔmTSS decreased significantly from 7.1 ± 7.3 at baseline to 1.8 ± 5.7 at week 24. C-reactive protein (CRP) was the only independent prognostic factor for joint damage progression at week 24, whereas SDAI and matrix metalloproteinase-3 levels were not. A very high proportion of patients with CRP levels <1.5 mg/dl (88 %) achieved structural remission. In terms of safety, the retention rate for all patients was favorable (80 %), and stomatitis was the only adverse event observed. No patient withdrew from the study because of infections. Conclusions Abatacept has favorable clinical and structural effects, inhibits radiographic progression, and has a good safety profile in routine clinical practice.
AB - Objectives Our objectives in this study were to determine the inhibitory effects of abatacept on joint damage and its clinical efficacy and safety in patients with rheumatoid arthritis (RA). Methods Fifty Japanese patients with RA were treated with abatacept for 24 weeks in routine clinical practice. Results At week 24, 20 % of patients achieved clinical remission [Simplified Disease Activity Index (SDAI) ≤3.3], whereas 50 % were in remission or had a low disease activity. Structural remission [progression of modified total Sharp score (ΔmTSS) ≤0.5] was achieved in 76 % of patients. The ΔmTSS decreased significantly from 7.1 ± 7.3 at baseline to 1.8 ± 5.7 at week 24. C-reactive protein (CRP) was the only independent prognostic factor for joint damage progression at week 24, whereas SDAI and matrix metalloproteinase-3 levels were not. A very high proportion of patients with CRP levels <1.5 mg/dl (88 %) achieved structural remission. In terms of safety, the retention rate for all patients was favorable (80 %), and stomatitis was the only adverse event observed. No patient withdrew from the study because of infections. Conclusions Abatacept has favorable clinical and structural effects, inhibits radiographic progression, and has a good safety profile in routine clinical practice.
KW - Abatacept
KW - Japanese patients
KW - Modified total Sharp score
KW - Radiographic outcome
KW - Rheumatoid arthritis
UR - http://www.scopus.com/inward/record.url?scp=84904975988&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84904975988&partnerID=8YFLogxK
U2 - 10.3109/14397595.2013.854051
DO - 10.3109/14397595.2013.854051
M3 - Article
C2 - 24261758
AN - SCOPUS:84904975988
VL - 24
SP - 42
EP - 51
JO - Modern Rheumatology
JF - Modern Rheumatology
SN - 1439-7595
IS - 1
ER -